No Data
Express News | Addex Therapeutics Shares Are Trading Lower. The Company Provided Preliminary Q3 Financial Results
addex therapeutics (ADXN.US) will release its financial report before the market opens on November 22nd.
$Addex Therapeutics (ADXN.US)$ will release its financial report before the market opens on November 22nd, investors are requested to pay attention. How was the previous performance? $Addex Therapeutics (ADXN.US)$'s revenue in 2024/Q2 was 0.115277 million francs, net income was 12.878632 million francs, and EPS was 9.6 francs. Revenue in 2023/Q3 was 0.327733 million francs, net income was -2.61707 million francs, and EPS was -3.6 francs. Futubull reminder: 1. Hong Kong stocks, U.S. stocks
Addex Provisional 2024 Third Quarter Results Showed Net Loss Compared to Second Quarter 2024
Why IRhythm Technologies Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket
What Makes Addex Therapeutics (ADXN) a New Buy Stock
Buy Rating Affirmed for Addex Therapeutics Amid Promising Clinical Developments and Strategic Neurosterix Spinout
No Data
No Data
Steve Kovacek : There’s only one way this train wreck is going…..down,down,down